Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization

Research Article

Anti-HER2 drugs are becoming an important therapeutic option for various solid tumors, increasing the need for HER2 status testing. Comprehensive genomic profiling (CGP) panels, including FoundationOne®CDx, are commonly used to assess ERBB2 (encoding for HER2) copy number alterations. We aimed to evaluate the analytical validity of FoundationOne®CDx assay, by comparing ERBB2 copy number data with traditional HER2 status by immunohistochemistry (IHC)/in situ hybridization (ISH) assays in a heterogeneous cohort of solid tumor samples.

Volume 111 Issue 3, June 2025

Research Article

Read the latest issue. It contains the following articles:
Associations between vascular endothelial growth factor polymorphisms and response to 5-FU-based pharmaceutical therapy in esophageal squamous cell carcinoma: A meta-analysis.
Adjuvant chemotherapy in elderly patients with HER2-negative early breast cancer: A systematic review and meta-analysis.
Towards a better registration of neuroendocrine neoplasms: The results of the Italian retrospective population-based study.
Clinical difference between solitary and multiple pulmonary adenocarcinoma nodules.
CT-based radiomics: A potential indicator of KRAS mutation in pulmonary adenocarcinoma.
Efficacy and safety of hepatic arterial infusion chemotherapy followed by transarterial embolization for hepatocellular carcinoma.
Prevalence of breast cancer in ovarian cancer patients and its impact on patient survival: An analysis of the surveillance, epidemiology, and end results data.
ESCO1 as a novel predictive biomarker and potential therapeutic target in renal cell carcinoma.
Exploratory analysis of the professional quality of life in an Italian radiotherapy department: The role of empathy and alexithymia.

Engagement in cancer clinical trials among a nationally representative cancer survivor sample: Motivators, barriers and opportunities for improvement

Research Article

Most patients with cancer do not participate in a clinical trial. Understanding clinical participation rates, and the barriers and motivators that influence participation may help identify opportunities for improvement in accrual. A cross-sectional analysis of cancer survivors was conducted using the Health Information National Trends Survey (HINTS) administered in 2020.

Clinicopathological characteristics and prognosis of cervical adenocarcinoma across diverse histological subtypes

Research Article

To investigate the clinical features and prognostic implications of different subtypes of cervical adenocarcinoma.
We examined 13,353 adenocarcinoma (AC) cases from the SEER database to identify distinct clinical characteristics and prognostic factors among various histological subtypes. Using the WHO classification and International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) codes, we categorized patients and assessed overall survival (OS) and cancer-specific survival (CSS) via Kaplan-Meier and Cox regression analyses. A nomogram was constructed to predict patient survival across subtypes.

Volume 111 Issue 2, April 2025

Research Article

Read the latest issue. It contains the following articles:
Associations between vascular endothelial growth factor polymorphisms and response to 5-FU-based pharmaceutical therapy in esophageal squamous cell carcinoma: A meta-analysis.
Adjuvant chemotherapy in elderly patients with HER2-negative early breast cancer: A systematic review and meta-analysis.
Towards a better registration of neuroendocrine neoplasms: The results of the Italian retrospective population-based study.
Clinical difference between solitary and multiple pulmonary adenocarcinoma nodules.
CT-based radiomics: A potential indicator of KRAS mutation in pulmonary adenocarcinoma.
Efficacy and safety of hepatic arterial infusion chemotherapy followed by transarterial embolization for hepatocellular carcinoma.
Prevalence of breast cancer in ovarian cancer patients and its impact on patient survival: An analysis of the surveillance, epidemiology, and end results data.
ESCO1 as a novel predictive biomarker and potential therapeutic target in renal cell carcinoma.
Exploratory analysis of the professional quality of life in an Italian radiotherapy department: The role of empathy and alexithymia.

Melanoma in children and adolescents: Distinct biology, evolving therapies, and unmet needs

Editorial

The incidence of melanoma is increasing worldwide, also among pediatric patients. According to the recent EUROCARE-6 report, cutaneous melanoma accounts for approximately 6% of all tumors in children, and about 10% among adolescents and young adults (AYAs) (i.e., patients aged 15-39 years).1 The reported incidence rate among patients aged <19 years is 0.43/100,000, rising to 6.9/100,000 among AYAs. As such, according to the definition adopted by European pediatric cooperative groups for rare childhood tumors (i.e., tumors with an annual incidence of <2 cases per million population), cutaneous melanoma can be considered a rare tumor in children, but not in AYAs.2